
Communicating Concerns About Nonspecific Changes on ECG
Communicating concerns about nonspecific changes on ECG Exercise caution when a patient presents with acute chest pain. The ability to explain the situation as clearly as possible is essential.
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval
Feb 4, 2025 · The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.. The active ingredient in Journavx is suzetrigine, a ...
6 Facts About Time in Range and the Glucose Management Indicator
Feb 21, 2024 · References: Pilla SJ, Segal JB, Maruthur NM. Primary care provides the majority of outpatient care for patients with diabetes in the US: NAMCS 2009-2015.
Prostate Cancer Treatment Challenge: Which Drugs to Use First
Jan 7, 2025 · Over the past 14 years, clinicians have seen rapid growth in their therapeutic armamentarium to treat advanced prostate cancer.They can now choose among 4 novel second-generation hormone therapies ...
Understanding the Mallampati score - Clinical Advisor
Feb 4, 2016 · In anesthesia, the Mallampati score (or Mallampati classification) is used to predict the ease of intubation. It can also be used to predict whether a patient might have obstructive sleep apnea.
WHY IS THIS PATIENT’S CK ELEVATED? - Clinical Advisor
May 29, 2008 · During an evaluation for myasthenia gravis, a 67-year-old white man on statin therapy was found to have a creatine kinase (CK) of 600 mg/dL (normal <200).
PA & NP Medical Guidance | Clinical Diagnosis & Treatment
Physician assistants and nurse practitioners use Clinical Advisor for updated medical guidance to diagnose and treat common medical conditions in daily practice.
When to treat high LDL with high HDL - Clinical Advisor
Apr 1, 2009 · What is the best therapeutic approach for asymptomatic patients with zero to two cardiac risk factors, elevated LDL (>130-160 mg/dL), and high HDL
Health Awareness Months 2025 - Clinical Advisor
Feb 9, 2023 · Health awareness campaigns occur all throughout the year in a wide variety of medical fields. These are when health awareness days, weeks, and months are happening this year.
REDEFINE 1 Trial: Superior Weight Loss Seen With CagriSema
Dec 26, 2024 · Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) in overweight or obese patients without type 2 diabetes.